查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1701376

Herceptin市场规模、份额、趋势分析报告：按产品、应用、付款人、分销管道、地区、细分市场预测，2025-2030 年

Herceptin Market Size, Share & Trends Analysis Report By Product (Biosimilar, Biologic) By Application (Breast Cancer, Stomach/Gastric Cancer), By Payer (Commercial/Private, Public), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

Herceptin市场的成长和趋势

根据Grand View Research, Inc.的最新报告，预计到2030年全球Herceptin市场规模将达到41亿美元，2025年至2030年期间的复合年增长率为5.5%。

Herceptin市场的主要驱动力是其在治疗 HER2 阳性癌症（尤其是乳癌和胃癌）方面的既定疗效。Herceptin透过直接抑制 HER2 受体、抑制肿瘤生长和活化免疫介导的细胞毒性，彻底改变了治疗模式。Herceptin被定位为早期和转移性癌症的标准治疗方法，支持其全球需求。Herceptin在联合治疗中发挥重要作用，尤其是与化疗和较新的 HER2标靶药物（联合治疗Pertuzumab使用，进一步增强了其治疗相关性。随着在新辅助和辅助治疗中核准，Herceptin的患者基础不断扩大，现实世界的证据继续支持Herceptin的长期生存益处。

然而，随着美国（2019年）和欧洲（2014年）关键专利到期，Herceptin市场正在发生重大变化，带来一波生物相似药竞争。这种变化导致了严重的定价压力，并降低了原创品牌产品的独家经营权，尤其是在价格敏感的市场。对此，罗氏实施了生命週期管理策略，包括开发皮下（SC）製剂和Phesgo（SC）（Pertuzumab和曲妥珠单抗的固定剂量组合），以提高便利性、缩短给药时间并维持患者忠诚度。这些创新不仅提高了医疗保健的效率，而且为生物相似药在临床实践中提供了竞争优势。

曲妥珠单抗生物相似药市场强劲且快速扩张，辉瑞、安进、Biocon Biologics、三星 Bioepis 和 Celltrion 等多家公司已在全球市场获得核准。曲妥珠单抗生物相似药在高所得地区和新兴地区的应用日益广泛，这使得 HER2标靶治疗的可及性变得更加民主，并显着降低了治疗成本。虽然这有利于医疗保健系统和患者，但也有可能侵蚀罗氏品牌Herceptin的市场占有率。全球监管机构正在透过明确的可互换指南和奖励采购模式支持生物相似药的采用，进一步加速其采用。在印度、中国和拉丁美洲等地区，特定国家的生物相似药数量正在增加，竞争日益激烈，尤其是在成本控制是优先考虑的地区。

儘管存在这些不利因素，Herceptin市场仍透过适应症扩展、策略合作和区域成长拥有巨大的机会。尤其是随着医疗保健系统寻求更有效的给药方式，SC Herceptin和 Phesgo 在门诊和社区环境中的使用预计将会扩大。此外，将曲妥珠单抗与免疫查核点抑制剂（如Pembrolizumab）组合方案治疗 HER2 阳性胃癌，为其应用开闢了新领域。这些新联合治疗目前正在临床试验中进行评估，可能会扩大Herceptin在传统 HER2 阳性适应症之外的作用。此外，儘管由于生物相似药的竞争导致单位价格下降，但中低收入国家意识的提高、筛检率的上升以及诊断途径的改善预计将推动销售量成长。

展望未来，Herceptin市场可能会稳定在一个新的平衡状态，即原始药物和生物相似药的共存成为常态。罗氏向增值产品和真实世界性能数据的策略转变对于保持其市场地位至关重要。同时，生物相似药製造商准备利用规模经济、成本领先和区域伙伴关係来渗透服务不足的市场。此外，新的给药创新和数位治疗监测工具可能会增强曲妥珠单抗在不断发展的治疗模式中的效用。总体而言，虽然Herceptin在独占权或定价权方面可能不再占上风，但它将继续在 HER2 标靶癌症治疗中发挥重要作用，特别是作为更广泛的组合策略和综合护理解决方案的一部分。

Herceptin市场报告重点

  • 从产品来看，随着Herceptin在美国和欧洲的主要专利到期到期，在已开发市场和新兴市场均被广泛采用的生物相似药将在2024年占据Herceptin市场的主导地位，占据50.93%的最大份额。多家製造商提供具有成本效益的曲妥珠单抗生物相似药，显着改善了 HER2标靶治疗的可及性，特别是在癌症负担高且医疗保健系统成本敏感的地区。有竞争力的定价、本地製造和支持性法律规范进一步刺激了生物相似药的广泛采用。相较之下，生物製药/原始药物（罗氏公司的Herceptin）领域占据第二大市场份额，但由于其市场独占权和销售量不断输给生物相似药，其市场份额正在下降。
  • 根据应用情况，乳癌预计将在 2024 年占据Herceptin市场的主导地位，份额为 57.68%，这得益于其作为 HER2 阳性乳癌的一线和辅助性治疗的既定用途。该药物在早期和转移性乳癌中的长期作用，加上强有力的临床证据和指南支持，确保了持续的需求。由于 HER2 阳性胃癌和胃食道癌的核准扩大以及它们与查核点抑制剂（如Pembrolizumab）的联合使用日益增多，预计预测期内胃癌/胃食道癌的复合年增长率将最快。
  • 根据付款人，私人/私人保险部门在 2024 年占据最大的市场份额，为 91.03%，这得益于新兴市场对品牌和生物仿製药曲妥珠单抗的广泛报销。 HER2标靶治疗通常包含在综合肿瘤福利计划中。公共卫生领域预计将出现加速成长，特别是在新兴经济体，这些国家的国家卫生计画正在扩大生物相似药的使用范围，将其作为原厂生技药品的经济有效的替代品。
  • 根据销售管道，医院药局将继续引领市场，2024 年的市场占有率为 51.77%，这反映了癌症中心对输液管理和监测的需求。Herceptin是一种输液製剂，癌症治疗方法的复杂性导致了医院系统中给药量的增加。由于Herceptin及其组合药物Phesgo（曲妥珠单抗 +Pertuzumab）的皮下製剂在门诊和居家医疗环境中得到越来越广泛的应用，为患者提供了更大的灵活性和便利性，预计专业药房的复合年增长率将最快。
  • 2024年4月，FDA加速核准Enhertu（fam-trastuzumab deruxtecan-nxki），用于治疗先前全身性治疗后病情进展的不可切除或转移性HER2阳性固体癌患者。这是HER2标靶治疗首次核准作为肿瘤诊断剂，将用途扩展到乳癌和胃癌等传统适应症之外。这项核准是基于 DESTINY-PanTumor02 试验的结果，该研究表明 ENHERTZ 对多种癌症表现出显着的反应率，包括胆道癌、膀胱癌和子宫内膜癌。这项发展显着扩展了 HER2标靶治疗的临床效用，并使 Enhertu 成为不断发展的精准肿瘤学领域的主要参与者。

目录

第一章调查方法与范围

第二章执行摘要

第三章Herceptin市场变数、趋势与范围

  • 市场展望
  • 市场动态
    • 市场成长要素分析
    • 市场限制因素分析
  • 商业环境分析
    • 产业分析-波特五力分析
    • PESTLE分析
    • 专利到期分析
    • 定价和报销方案
    • 併购与交易
    • 学名药/生物相似药的影响

第四章Herceptin市场：按产品分類的业务分析

  • 2024年及2030年的产品市场占有率
  • 产品细分仪表板
  • 市场规模、预测与趋势分析（按产品，2018-2030 年）
  • 生物製药
  • 生物相似药

第五章Herceptin市场：按应用进行的业务分析

  • 2024 年和 2030 年应用市场占有率
  • 应用程式细分仪表板
  • 市场规模、预测与趋势分析（按应用，2018-2030 年）
  • 乳癌
  • 胃癌

第六章Herceptin市场：按付款者进行的业务分析

  • 2024 年及 2030 年付款人市场占有率
  • 付款人细分仪表板
  • 付款人的市场规模、预测和趋势分析（2018-2030）
  • 商业/个人
  • 公共

第七章Herceptin市场：按分销管道进行的业务分析

  • 2024年及2030年分销通路市场占有率
  • 分销通路细分仪表板
  • 按分销管道分類的市场规模、预测和趋势分析（2018-2030 年）
  • 医院药房
  • 专业药房

第八章Herceptin市场：区域估计和趋势分析

  • 2024 年及 2030 年区域市场占有率分析
  • 区域市场仪表板
  • 2018年至2030年市场规模与预测趋势分析：
  • 北美洲
    • 2018-2030年各国情况
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第九章竞争格局

  • 参与企业概况
  • 企业市场分析
  • 公司分类
  • 战略地图
  • 公司简介/列表
    • Roche Holding AG（Genentech）
    • Pfizer Inc.
    • Samsung Bioepis Co., Ltd.
    • Amgen Inc.
    • Celltrion Healthcare Co., Ltd.
    • Biocon Limited
    • Mylan NV（Viatris）
    • Prestige Biopharma
    • Shanghai Henlius Biotech, Inc.
    • AryoGen Pharmed
    • Dr. Reddy's Laboratories
Product Code: GVR-4-68040-540-6

Herceptin Market Growth & Trends:

The global herceptin market size is anticipated to reach USD 4.10 billion by 2030 and is projected to grow at a CAGR of 5.5% from 2025 to 2030, according to a new report by Grand View Research, Inc. The key driver of the Herceptin market is its established efficacy in treating HER2-positive cancers, particularly breast and gastric cancers. As one of the earliest and most successful targeted therapies, Herceptin revolutionized the treatment paradigm by directly inhibiting the HER2 receptor, halting tumor growth, and activating immune-mediated cytotoxicity. Its inclusion as a standard-of-care therapy in both early-stage and metastatic settings continues to anchor its global demand. Herceptin's role in combination regimens-especially with chemotherapy and newer HER2-targeted agents like pertuzumab-further boosts its therapeutic relevance. Approvals in neoadjuvant and adjuvant contexts have expanded its patient base, while real-world evidence continues to support its long-term survival benefits.

However, Herceptin's market has undergone significant transformation due to the expiration of key patents-in the U.S. (2019) and Europe (2014)-which has opened the door to a wave of biosimilar competition. This shift has led to intense pricing pressures and reduced exclusivity for the originator product, especially in price-sensitive markets. In response, Roche has implemented lifecycle management strategies, including the development of a subcutaneous (SC) formulation and the co-formulated fixed-dose combination Phesgo (pertuzumab + trastuzumab SC), aimed at improving convenience, reducing administration time, and maintaining patient loyalty. These innovations not only enhance healthcare efficiency but also offer a competitive edge against biosimilars in clinical practice.

The biosimilar landscape for trastuzumab is robust and rapidly expanding, with multiple players such as Pfizer, Amgen, Biocon Biologics, Samsung Bioepis, and Celltrion securing approvals across global markets. The growing adoption of trastuzumab biosimilars in both high-income and emerging regions has democratized access to HER2-targeted therapy, significantly lowering treatment costs. While this benefits healthcare systems and patients, it also presents market share erosion risks for Roche's branded Herceptin. Regulatory authorities worldwide have supported biosimilar adoption through clear interchangeability guidelines and incentivized procurement models, further accelerating their uptake. The increasing number of country-specific biosimilars in regions like India, China, and Latin America is intensifying competition, especially where cost containment is a priority.

Despite these headwinds, opportunities remain strong in the Herceptin market through expanding indications, strategic partnerships, and regional growth. The uptake of SC Herceptin and Phesgo in outpatient and community settings is poised to grow, particularly as healthcare systems seek more efficient delivery options. Additionally, the inclusion of trastuzumab in combination regimens with immune checkpoint inhibitors, such as pembrolizumab in HER2-positive gastric cancer, is opening new frontiers for its use. These novel combinations are being evaluated in clinical trials and could expand Herceptin's role beyond traditional HER2-positive indications. Furthermore, rising awareness, increasing screening rates, and improving access to diagnostics in low-to-middle-income countries are expected to fuel volume growth, even if unit prices decline due to biosimilar competition.

Looking ahead, the Herceptin market will likely stabilize at a new equilibrium, where originator and biosimilar coexistence is the norm. Roche's strategic pivot toward value-added products and real-world outcomes data will be critical in retaining market presence. Meanwhile, biosimilar manufacturers are poised to benefit from scale, cost leadership, and local partnerships, which will help them penetrate underserved markets. Emerging delivery innovations and digital treatment monitoring tools may also enhance trastuzumab's utility in evolving care models. Overall, while Herceptin may no longer dominate in terms of exclusivity or pricing power, it will continue to play a pivotal role in HER2-targeted oncology, especially as part of broader combination strategies and integrated care solutions.

Herceptin Market Report Highlights:

  • Based on product, biosimilars dominated the Herceptin market in 2024, accounting for the largest share of 50.93%, driven by widespread adoption across both developed and emerging markets following the expiration of Herceptin's key patents in the U.S. and Europe. The availability of cost-effective trastuzumab biosimilars from multiple manufacturers has significantly improved access to HER2-targeted therapy, especially in regions with high cancer burden and cost-sensitive healthcare systems. Competitive pricing, local manufacturing, and supportive regulatory frameworks have further fueled biosimilar uptake. In contrast, the biologic/originator segment (Roche's Herceptin) holds the second-largest share but is witnessing a declining trend, as it continues to lose market exclusivity and volume to biosimilars.
  • Based on application, breast cancer dominated the Herceptin market in 2024 with a share of 57.68%, driven by its established use as a first-line and adjuvant therapy in HER2-positive breast cancer. The drug's long-standing role in both early-stage and metastatic breast cancer, combined with strong clinical evidence and guideline support, has ensured continued demand. Stomach/gastric cancer is projected to grow at the fastest CAGR over the forecast period, supported by expanded approvals for HER2-positive gastric and gastroesophageal cancers and growing use in combination with checkpoint inhibitors like pembrolizumab.
  • Based on payer, the commercial/private insurance segment accounted for the largest share at 91.03% in 2024, due to broad reimbursement for branded and biosimilar trastuzumab across developed markets. Access to HER2-targeted therapy is typically covered under comprehensive oncology benefit plans. The public insurance segment is expected to experience faster growth, particularly in emerging economies where national health programs are expanding access to biosimilars as cost-effective alternatives to originator biologics.
  • Based on distribution channel, hospital pharmacies remained the leading segment with a 51.77% market share in 2024, reflecting the need for infusion-based administration and monitoring within oncology centers. Herceptin's IV formulation and the complexity of oncology regimens reinforce its delivery through hospital-based systems. Specialty pharmacies are projected to register the fastest CAGR, as the subcutaneous formulation of Herceptin and the combination product Phesgo (trastuzumab + pertuzumab) become more widely adopted in outpatient and home-care settings, offering greater flexibility and improved patient convenience.
  • In April 2024, the FDA granted accelerated approval to Enhertu (fam-trastuzumab deruxtecan-nxki) for the treatment of HER2-positive solid tumors that are unresectable or metastatic and have progressed following prior systemic treatment. This marks the first tumor-agnostic approval for a HER2-targeted therapy, expanding its use beyond traditional indications like breast and gastric cancers. The approval was based on results from the DESTINY-PanTumor02 trial, where Enhertu demonstrated meaningful response rates across multiple cancer types, including biliary tract, bladder, and endometrial cancers. This development significantly broadens the clinical utility of HER2-targeted therapies and positions Enhertu as a major player in the evolving landscape of precision oncology.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Application
    • 1.2.3. Payer
    • 1.2.4. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Herceptin Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Patent Expiry Analysis
    • 3.3.4. Pricing and Reimbursement Scenario
    • 3.3.5. M&A and Deals
    • 3.3.6. Impact of Generics/Biosimilars

Chapter 4. Herceptin Market: Product Business Analysis

  • 4.1. Product Market Share, 2024 & 2030
  • 4.2. Product Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Product, 2018 to 2030 (USD Million)
  • 4.4. Biologic
    • 4.4.1. Biologic Market, 2018 - 2030 (USD Million)
  • 4.5. Biosimilar
    • 4.5.1. Biosimilar Market, 2018 - 2030 (USD Million)

Chapter 5. Herceptin Market: Application Business Analysis

  • 5.1. Application Market Share, 2024 & 2030
  • 5.2. Application Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Application, 2018 to 2030 (USD Million)
  • 5.4. Breast Cancer
    • 5.4.1. Breast Cancer Market, 2018 - 2030 (USD Million)
  • 5.5. Stomach/Gastric Cancer
    • 5.5.1. Stomach/Gastric Cancer Market, 2018 - 2030 (USD Million)

Chapter 6. Herceptin Market: Payer Business Analysis

  • 6.1. Payer Market Share, 2024 & 2030
  • 6.2. Payer Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Payer, 2018 to 2030 (USD Million)
  • 6.4. Commercial/Private
    • 6.4.1. Commercial/Private Market, 2018 - 2030 (USD Million)
  • 6.5. Public
    • 6.5.1. Public Market, 2018 - 2030 (USD Million)

Chapter 7. Herceptin Market: Distribution Channel Business Analysis

  • 7.1. Distribution Channel Market Share, 2024 & 2030
  • 7.2. Distribution Channel Segment Dashboard
  • 7.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
  • 7.4. Hospital Pharmacy
    • 7.4.1. Hospital Pharmacy Market, 2018 - 2030 (USD Million)
  • 7.5. Specialty Pharmacy
    • 7.5.1. Specialty Pharmacy Market, 2018 - 2030 (USD Million)

Chapter 8. Herceptin Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Share Analysis, 2024 & 2030
  • 8.2. Regional Market Dashboard
  • 8.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
  • 8.4. North America
    • 8.4.1. North America Herceptin Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 8.4.2. U.S.
      • 8.4.2.1. Key Country Dynamics
      • 8.4.2.2. Target Disease Prevalence
      • 8.4.2.3. Regulatory Framework
      • 8.4.2.4. Reimbursement Framework
      • 8.4.2.5. U.S. Herceptin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.3. Canada
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Target Disease Prevalence
      • 8.4.3.3. Regulatory Framework
      • 8.4.3.4. Reimbursement Framework
      • 8.4.3.5. Canada Herceptin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.4. Mexico
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. Target Disease Prevalence
      • 8.4.4.3. Regulatory Framework
      • 8.4.4.4. Reimbursement Framework
      • 8.4.4.5. Mexico Herceptin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5. Europe
    • 8.5.1. Europe Herceptin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.2. UK
      • 8.5.2.1. Key Country Dynamics
      • 8.5.2.2. Target Disease Prevalence
      • 8.5.2.3. Regulatory Framework
      • 8.5.2.4. Reimbursement Framework
      • 8.5.2.5. UK Herceptin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.3. Germany
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Target Disease Prevalence
      • 8.5.3.3. Regulatory Framework
      • 8.5.3.4. Reimbursement Framework
      • 8.5.3.5. Germany Herceptin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.4. France
      • 8.5.4.1. Key Country Dynamics
      • 8.5.4.2. Target Disease Prevalence
      • 8.5.4.3. Regulatory Framework
      • 8.5.4.4. Reimbursement Framework
      • 8.5.4.5. France Herceptin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.5. Italy
      • 8.5.5.1. Key Country Dynamics
      • 8.5.5.2. Target Disease Prevalence
      • 8.5.5.3. Regulatory Framework
      • 8.5.5.4. Reimbursement Framework
      • 8.5.5.5. Italy Herceptin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.6. Spain
      • 8.5.6.1. Key Country Dynamics
      • 8.5.6.2. Target Disease Prevalence
      • 8.5.6.3. Regulatory Framework
      • 8.5.6.4. Reimbursement Framework
      • 8.5.6.5. Spain Herceptin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.7. Denmark
      • 8.5.7.1. Key Country Dynamics
      • 8.5.7.2. Target Disease Prevalence
      • 8.5.7.3. Regulatory Framework
      • 8.5.7.4. Reimbursement Framework
      • 8.5.7.5. Denmark Herceptin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.8. Sweden
      • 8.5.8.1. Key Country Dynamics
      • 8.5.8.2. Target Disease Prevalence
      • 8.5.8.3. Regulatory Framework
      • 8.5.8.4. Reimbursement Framework
      • 8.5.8.5. Sweden Herceptin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.9. Norway
      • 8.5.9.1. Key Country Dynamics
      • 8.5.9.2. Target Disease Prevalence
      • 8.5.9.3. Regulatory Framework
      • 8.5.9.4. Reimbursement Framework
      • 8.5.9.5. Norway Herceptin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6. Asia Pacific
    • 8.6.1. Asia Pacific Herceptin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.2. Japan
      • 8.6.2.1. Key Country Dynamics
      • 8.6.2.2. Target Disease Prevalence
      • 8.6.2.3. Regulatory Framework
      • 8.6.2.4. Reimbursement Framework
      • 8.6.2.5. Japan Herceptin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.3. China
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Target Disease Prevalence
      • 8.6.3.3. Regulatory Framework
      • 8.6.3.4. Reimbursement Framework
      • 8.6.3.5. China Herceptin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.4. India
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. Target Disease Prevalence
      • 8.6.4.3. Regulatory Framework
      • 8.6.4.4. Reimbursement Framework
      • 8.6.4.5. India Herceptin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.5. Australia
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Target Disease Prevalence
      • 8.6.5.3. Regulatory Framework
      • 8.6.5.4. Reimbursement Framework
      • 8.6.5.5. Australia Herceptin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.6. South Korea
      • 8.6.6.1. Key Country Dynamics
      • 8.6.6.2. Target Disease Prevalence
      • 8.6.6.3. Regulatory Framework
      • 8.6.6.4. Reimbursement Framework
      • 8.6.6.5. South Korea Herceptin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.7. Thailand
      • 8.6.7.1. Key Country Dynamics
      • 8.6.7.2. Target Disease Prevalence
      • 8.6.7.3. Regulatory Framework
      • 8.6.7.4. Reimbursement Framework
      • 8.6.7.5. Thailand Herceptin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.7. Latin America
    • 8.7.1. Latin America Herceptin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.7.2. Brazil
      • 8.7.2.1. Key Country Dynamics
      • 8.7.2.2. Target Disease Prevalence
      • 8.7.2.3. Regulatory Framework
      • 8.7.2.4. Reimbursement Framework
      • 8.7.2.5. Japan Herceptin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.7.3. Argentina
      • 8.7.3.1. Key Country Dynamics
      • 8.7.3.2. Target Disease Prevalence
      • 8.7.3.3. Regulatory Framework
      • 8.7.3.4. Reimbursement Framework
      • 8.7.3.5. China Herceptin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.8. Middle East and Africa
    • 8.8.1. Middle East and Africa Herceptin Market Estimates and Forecasts, 2017 - 2030 (USD Million)
    • 8.8.2. South Africa
      • 8.8.2.1. Key Country Dynamics
      • 8.8.2.2. Target Disease Prevalence
      • 8.8.2.3. Regulatory Framework
      • 8.8.2.4. Reimbursement Framework
      • 8.8.2.5. South Africa Herceptin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.8.3. Saudi Arabia
      • 8.8.3.1. Key Country Dynamics
      • 8.8.3.2. Target Disease Prevalence
      • 8.8.3.3. Regulatory Framework
      • 8.8.3.4. Reimbursement Framework
      • 8.8.3.5. Saudi Arabia Herceptin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.8.4. UAE
      • 8.8.4.1. Key Country Dynamics
      • 8.8.4.2. Target Disease Prevalence
      • 8.8.4.3. Regulatory Framework
      • 8.8.4.4. Reimbursement Framework
      • 8.8.4.5. UAE Herceptin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.8.5. Kuwait
      • 8.8.5.1. Key Country Dynamics
      • 8.8.5.2. Target Disease Prevalence
      • 8.8.5.3. Regulatory Framework
      • 8.8.5.4. Reimbursement Framework
      • 8.8.5.5. Kuwait Herceptin Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Participant Overview
  • 9.2. Company Market Position Analysis
  • 9.3. Company Categorization
  • 9.4. Strategy Mapping
  • 9.5. Company Profiles/Listing
    • 9.5.1. Roche Holding AG (Genentech)
      • 9.5.1.1. Overview
      • 9.5.1.2. Financial Performance
      • 9.5.1.3. Product Benchmarking
      • 9.5.1.4. Strategic Initiatives
    • 9.5.2. Pfizer Inc.
      • 9.5.2.1. Overview
      • 9.5.2.2. Financial Performance
      • 9.5.2.3. Product Benchmarking
      • 9.5.2.4. Strategic Initiatives
    • 9.5.3. Samsung Bioepis Co., Ltd.
      • 9.5.3.1. Overview
      • 9.5.3.2. Financial Performance
      • 9.5.3.3. Product Benchmarking
      • 9.5.3.4. Strategic Initiatives
    • 9.5.4. Amgen Inc.
      • 9.5.4.1. Overview
      • 9.5.4.2. Financial Performance
      • 9.5.4.3. Product Benchmarking
      • 9.5.4.4. Strategic Initiatives
    • 9.5.5. Celltrion Healthcare Co., Ltd.
      • 9.5.5.1. Overview
      • 9.5.5.2. Financial Performance
      • 9.5.5.3. Product Benchmarking
      • 9.5.5.4. Strategic Initiatives
    • 9.5.6. Biocon Limited
      • 9.5.6.1. Overview
      • 9.5.6.2. Financial Performance
      • 9.5.6.3. Product Benchmarking
      • 9.5.6.4. Strategic Initiatives
    • 9.5.7. Mylan N.V. (Viatris)
      • 9.5.7.1. Overview
      • 9.5.7.2. Financial Performance
      • 9.5.7.3. Product Benchmarking
      • 9.5.7.4. Strategic Initiatives
    • 9.5.8. Prestige Biopharma
      • 9.5.8.1. Overview
      • 9.5.8.2. Financial Performance
      • 9.5.8.3. Product Benchmarking
      • 9.5.8.4. Strategic Initiatives
    • 9.5.9. Shanghai Henlius Biotech, Inc.
      • 9.5.9.1. Overview
      • 9.5.9.2. Financial Performance
      • 9.5.9.3. Product Benchmarking
      • 9.5.9.4. Strategic Initiatives
    • 9.5.10. AryoGen Pharmed
      • 9.5.10.1. Overview
      • 9.5.10.2. Financial Performance
      • 9.5.10.3. Product Benchmarking
      • 9.5.10.4. Strategic Initiatives
    • 9.5.11. Dr. Reddy's Laboratories
      • 9.5.11.1. Overview
      • 9.5.11.2. Financial Performance
      • 9.5.11.3. Product Benchmarking
      • 9.5.11.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global Herceptin market, by region, 2018 - 2030 (USD Million)
  • Table 4 Global Herceptin market, by product, 2018 - 2030 (USD Million)
  • Table 5 Global Herceptin market, by application, 2018 - 2030 (USD Million)
  • Table 6 Global Herceptin market, by dosage form, 2018 - 2030 (USD Million)
  • Table 7 Global Herceptin market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 8 North America Herceptin market, by country, 2018 - 2030 (USD Million)
  • Table 9 North America Herceptin market, by product, 2018 - 2030 (USD Million)
  • Table 10 North America Herceptin market, by application, 2018 - 2030 (USD Million)
  • Table 11 North America Herceptin market, by dosage form, 2018 - 2030 (USD Million)
  • Table 12 North America Herceptin market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 13 U.S. Herceptin market, by product, 2018 - 2030 (USD Million)
  • Table 14 U.S. Herceptin market, by application, 2018 - 2030 (USD Million)
  • Table 15 U.S. Herceptin market, by dosage form, 2018 - 2030 (USD Million)
  • Table 16 U.S. Herceptin market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 17 Canada Herceptin market, by product, 2018 - 2030 (USD Million)
  • Table 18 Canada Herceptin market, by application, 2018 - 2030 (USD Million)
  • Table 19 Canada Herceptin market, by dosage form, 2018 - 2030 (USD Million)
  • Table 20 Canada Herceptin market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 21 Mexico Herceptin market, by product, 2018 - 2030 (USD Million)
  • Table 22 Mexico Herceptin market, by application, 2018 - 2030 (USD Million)
  • Table 23 Mexico Herceptin market, by dosage form, 2018 - 2030 (USD Million)
  • Table 24 Mexico Herceptin market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 25 Europe Herceptin market, by country, 2018 - 2030 (USD Million)
  • Table 26 Europe Herceptin market, by product, 2018 - 2030 (USD Million)
  • Table 27 Europe Herceptin market, by application, 2018 - 2030 (USD Million)
  • Table 28 Europe Herceptin market, by dosage form, 2018 - 2030 (USD Million)
  • Table 29 Europe Herceptin market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 30 UK Herceptin market, by product, 2018 - 2030 (USD Million)
  • Table 31 UK Herceptin market, by application, 2018 - 2030 (USD Million)
  • Table 32 UK Herceptin market, by dosage form, 2018 - 2030 (USD Million)
  • Table 33 UK Herceptin market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 34 Germany Herceptin market, by product, 2018 - 2030 (USD Million)
  • Table 35 Germany Herceptin market, by application, 2018 - 2030 (USD Million)
  • Table 36 Germany Herceptin market, by dosage form, 2018 - 2030 (USD Million)
  • Table 37 Germany Herceptin market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 38 France Herceptin market, by product, 2018 - 2030 (USD Million)
  • Table 39 France Herceptin market, by application, 2018 - 2030 (USD Million)
  • Table 40 France Herceptin market, by dosage form, 2018 - 2030 (USD Million)
  • Table 41 France Herceptin market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 42 Italy Herceptin market, by product, 2018 - 2030 (USD Million)
  • Table 43 Italy Herceptin market, by application, 2018 - 2030 (USD Million)
  • Table 44 Italy Herceptin market, by dosage form, 2018 - 2030 (USD Million)
  • Table 45 Italy Herceptin market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 46 Spain Herceptin market, by product, 2018 - 2030 (USD Million)
  • Table 47 Spain Herceptin market, by application, 2018 - 2030 (USD Million)
  • Table 48 Spain Herceptin market, by dosage form, 2018 - 2030 (USD Million)
  • Table 49 Spain Herceptin market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 50 Norway Herceptin market, by product, 2018 - 2030 (USD Million)
  • Table 51 Norway Herceptin market, by application, 2018 - 2030 (USD Million)
  • Table 52 Norway Herceptin market, by dosage form, 2018 - 2030 (USD Million)
  • Table 53 Norway Herceptin market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 54 Denmark Herceptin market, by product, 2018 - 2030 (USD Million)
  • Table 55 Denmark Herceptin market, by application, 2018 - 2030 (USD Million)
  • Table 56 Denmark Herceptin market, by dosage form, 2018 - 2030 (USD Million)
  • Table 57 Denmark Herceptin market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 58 Sweden Herceptin market, by product, 2018 - 2030 (USD Million)
  • Table 59 Sweden Herceptin market, by application, 2018 - 2030 (USD Million)
  • Table 60 Sweden Herceptin market, by dosage form, 2018 - 2030 (USD Million)
  • Table 61 Sweden Herceptin market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 62 Asia Pacific Herceptin market, by country, 2018 - 2030 (USD Million)
  • Table 63 Asia Pacific Herceptin market, by product, 2018 - 2030 (USD Million)
  • Table 64 Asia Pacific Herceptin market, by application, 2018 - 2030 (USD Million)
  • Table 65 Asia Pacific Herceptin market, by dosage form, 2018 - 2030 (USD Million)
  • Table 66 Asia Pacific Herceptin market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 67 Japan Herceptin market, by product, 2018 - 2030 (USD Million)
  • Table 68 Japan Herceptin market, by application, 2018 - 2030 (USD Million)
  • Table 69 Japan Herceptin market, by dosage form, 2018 - 2030 (USD Million)
  • Table 70 Japan Herceptin market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 71 China Herceptin market, by product, 2018 - 2030 (USD Million)
  • Table 72 China Herceptin market, by application, 2018 - 2030 (USD Million)
  • Table 73 China Herceptin market, by dosage form, 2018 - 2030 (USD Million)
  • Table 74 China Herceptin market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 75 India Herceptin market, by product, 2018 - 2030 (USD Million)
  • Table 76 India Herceptin market, by application, 2018 - 2030 (USD Million)
  • Table 77 India Herceptin market, by dosage form, 2018 - 2030 (USD Million)
  • Table 78 India Herceptin market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 79 Australia Herceptin market, by product, 2018 - 2030 (USD Million)
  • Table 80 Australia Herceptin market, by application, 2018 - 2030 (USD Million)
  • Table 81 Australia Herceptin market, by dosage form, 2018 - 2030 (USD Million)
  • Table 82 Australia Herceptin market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 83 South Korea Herceptin market, by product, 2018 - 2030 (USD Million)
  • Table 84 South Korea Herceptin market, by application, 2018 - 2030 (USD Million)
  • Table 85 South Korea Herceptin market, by dosage form, 2018 - 2030 (USD Million)
  • Table 86 South Korea Herceptin market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 87 Thailand Herceptin market, by product, 2018 - 2030 (USD Million)
  • Table 88 Thailand Herceptin market, by application, 2018 - 2030 (USD Million)
  • Table 89 Thailand Herceptin market, by dosage form, 2018 - 2030 (USD Million)
  • Table 90 Thailand Herceptin market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 91 Latin America Herceptin market, by country, 2018 - 2030 (USD Million)
  • Table 92 Latin America Herceptin market, by product, 2018 - 2030 (USD Million)
  • Table 93 Latin America Herceptin market, by application, 2018 - 2030 (USD Million)
  • Table 94 Latin America Herceptin market, by dosage form, 2018 - 2030 (USD Million)
  • Table 95 Latin America Herceptin market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 96 Brazil Herceptin market, by product, 2018 - 2030 (USD Million)
  • Table 97 Brazil Herceptin market, by application, 2018 - 2030 (USD Million)
  • Table 98 Brazil Herceptin market, by dosage form, 2018 - 2030 (USD Million)
  • Table 99 Brazil Herceptin market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 100 Argentina Herceptin market, by product, 2018 - 2030 (USD Million)
  • Table 101 Argentina Herceptin market, by application, 2018 - 2030 (USD Million)
  • Table 102 Argentina Herceptin market, by dosage form, 2018 - 2030 (USD Million)
  • Table 103 Argentina Herceptin market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 104 Middle East & Africa Herceptin market, by country, 2018 - 2030 (USD Million)
  • Table 105 Middle East & Africa Herceptin market, by product, 2018 - 2030 (USD Million)
  • Table 106 Middle East & Africa Herceptin market, by application, 2018 - 2030 (USD Million)
  • Table 107 Middle East & Africa Herceptin market, by dosage form, 2018 - 2030 (USD Million)
  • Table 108 Middle East & Africa Herceptin market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 109 South Africa Herceptin market, by product, 2018 - 2030 (USD Million)
  • Table 110 South Africa Herceptin market, by application, 2018 - 2030 (USD Million)
  • Table 111 South Africa Herceptin market, by dosage form, 2018 - 2030 (USD Million)
  • Table 112 South Africa Herceptin market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 113 Saudi Arabia Herceptin market, by product, 2018 - 2030 (USD Million)
  • Table 114 Saudi Arabia Herceptin market, by application, 2018 - 2030 (USD Million)
  • Table 115 Saudi Arabia Herceptin market, by dosage form, 2018 - 2030 (USD Million)
  • Table 116 Saudi Arabia Herceptin market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 117 UAE Herceptin market, by product, 2018 - 2030 (USD Million)
  • Table 118 UAE Herceptin market, by application, 2018 - 2030 (USD Million)
  • Table 119 UAE Herceptin market, by dosage form, 2018 - 2030 (USD Million)
  • Table 120 UAE Herceptin market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 121 Kuwait Herceptin market, by product, 2018 - 2030 (USD Million)
  • Table 122 Kuwait Herceptin market, by application, 2018 - 2030 (USD Million)
  • Table 123 Kuwait Herceptin market, by dosage form, 2018 - 2030 (USD Million)
  • Table 124 Kuwait Herceptin market, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Herceptin market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Application outlook (USD Million)
  • Fig. 10 Competitive landscape
  • Fig. 11 Herceptin market dynamics
  • Fig. 12 Herceptin market: Porter's five forces analysis
  • Fig. 13 Herceptin market: PESTLE analysis
  • Fig. 14 Herceptin market by product product (USD Million)
  • Fig. 15 Biologic product revenue trend in Herceptin market (USD Million)
  • Fig. 16 Biosimilar product market share analysis (USD Million)
  • Fig. 17 Herceptin market application segmentation (USD Million)
  • Fig. 18 Breast cancer treatment revenue share in Herceptin market (USD Million)
  • Fig. 19 Gastric cancer Herceptin usage trend and forecast (USD Million)
  • Fig. 20 Herceptin market by payer product (USD Million)
  • Fig. 21 Commercial/private insurance coverage and adoption trend (USD Million)
  • Fig. 22 Public insurance reimbursement growth in Herceptin market (USD Million)
  • Fig. 23 Herceptin distribution channel market share (USD Million)
  • Fig. 24 Hospital pharmacy distribution analysis for Herceptin (USD Million)
  • Fig. 25 Specialty pharmacy Herceptin delivery growth trend (USD Million)
  • Fig. 26 Herceptin market revenue, by region
  • Fig. 27 Regional marketplace: Key takeaways
  • Fig. 28 North America Herceptin market, 2018 - 2030 (USD Million)
  • Fig. 29 U.S. country dynamics
  • Fig. 30 U.S. Herceptin market, 2018 - 2030 (USD Million)
  • Fig. 31 Canada country dynamics
  • Fig. 32 Canada Herceptin market, 2018 - 2030 (USD Million)
  • Fig. 33 Mexico country dynamics
  • Fig. 34 Mexico Herceptin market, 2018 - 2030 (USD Million)
  • Fig. 35 Europe Herceptin market, 2018 - 2030 (USD Million)
  • Fig. 36 UK country dynamics
  • Fig. 37 UK Herceptin market, 2018 - 2030 (USD Million)
  • Fig. 38 Germany country dynamics
  • Fig. 39 Germany Herceptin market, 2018 - 2030 (USD Million)
  • Fig. 40 France country dynamics
  • Fig. 41 France Herceptin market, 2018 - 2030 (USD Million)
  • Fig. 42 Italy country dynamics
  • Fig. 43 Italy Herceptin market, 2018 - 2030 (USD Million)
  • Fig. 44 Spain country dynamics
  • Fig. 45 Spain Herceptin market, 2018 - 2030 (USD Million)
  • Fig. 46 Norway country dynamics
  • Fig. 47 Norway Herceptin market, 2018 - 2030 (USD Million)
  • Fig. 48 Sweden country dynamics
  • Fig. 49 Sweden Herceptin market, 2018 - 2030 (USD Million)
  • Fig. 50 Denmark country dynamics
  • Fig. 51 Denmark Herceptin market, 2018 - 2030 (USD Million)
  • Fig. 52 Asia-Pacific Herceptin market, 2018 - 2030 (USD Million)
  • Fig. 53 Japan country dynamics
  • Fig. 54 Japan Herceptin market, 2018 - 2030 (USD Million)
  • Fig. 55 China country dynamics
  • Fig. 56 China Herceptin market, 2018 - 2030 (USD Million)
  • Fig. 57 India country dynamics
  • Fig. 58 India Herceptin market, 2018 - 2030 (USD Million)
  • Fig. 59 Australia country dynamics
  • Fig. 60 Australia Herceptin market, 2018 - 2030 (USD Million)
  • Fig. 61 South Korea country dynamics
  • Fig. 62 South Korea Herceptin market, 2018 - 2030 (USD Million)
  • Fig. 63 Thailand country dynamics
  • Fig. 64 Thailand Herceptin market, 2018 - 2030 (USD Million)
  • Fig. 65 Latin America Herceptin market, 2018 - 2030 (USD Million)
  • Fig. 66 Brazil country dynamics
  • Fig. 67 Brazil Herceptin market, 2018 - 2030 (USD Million)
  • Fig. 68 Argentina country dynamics
  • Fig. 69 Argentina Herceptin market, 2018 - 2030 (USD Million)
  • Fig. 70 Middle East & Africa (MEA) Herceptin market, 2018 - 2030 (USD Million)
  • Fig. 71 South Africa country dynamics
  • Fig. 72 South Africa Herceptin market, 2018 - 2030 (USD Million)
  • Fig. 73 Saudi Arabia country dynamics
  • Fig. 74 Saudi Arabia Herceptin market, 2018 - 2030 (USD Million)
  • Fig. 75 UAE country dynamics
  • Fig. 76 UAE Herceptin market, 2018 - 2030 (USD Million)
  • Fig. 77 Kuwait country dynamics
  • Fig. 78 Kuwait Herceptin market, 2018 - 2030 (USD Million)
  • Fig. 79 Company categorization
  • Fig. 80 Company market position analysis
  • Fig. 81 Strategic framework